CTMX

1.09

0.91% -0.01

Dopo l'orario di chiusura: 1.07 -0.02 -1.83%

Cytomx Therapeutics Inc (CTMX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.10

Aprire:

$1.06

Volume 24 ore:

967.05K

Relative Volume:

0.86

Capitalizzazione di mercato:

$85.30M

Reddito:

$101.21M

Utile/perdita netta:

$-569.00K

Rapporto P/E:

-1.2976

EPS:

-0.84

Flusso di cassa netto:

$-56.88M

1 W Prestazione:

-1.80%

1M Prestazione:

+25.27%

6M Prestazione:

-14.84%

1 anno Prestazione:

-18.66%

Intervallo 1D:

$1.03

$1.10

Intervallo di 1 settimana:

$1.00

$1.16

Portata 52W:

$0.833

$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Nome

Cytomx Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

650.515.3185

Indirizzo

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Dipendente

122

Cinguettio

@cytomxinc

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

CTMX's Discussions on Twitter

Confronta CTMX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTMX Cytomx Therapeutics Inc	1.09	85.30M	101.21M	-569.00K	-56.88M	-0.02
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-05-09	Aggiornamento	Wedbush	Neutral → Outperform
2024-05-06	Aggiornamento	Jefferies	Hold → Buy
2024-04-22	Aggiornamento	JP Morgan	Underweight → Neutral
2022-11-14	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-07-07	Downgrade	Jefferies	Buy → Hold
2022-07-07	Downgrade	Mizuho	Buy → Neutral
2022-07-07	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-07	Downgrade	Wedbush	Outperform → Neutral
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2022-01-18	Aggiornamento	Barclays	Underweight → Overweight
2021-11-15	Iniziato	BTIG Research	Buy
2021-05-28	Downgrade	Barclays	Equal Weight → Underweight
2021-03-29	Iniziato	JP Morgan	Overweight
2021-03-23	Aggiornamento	Jefferies	Hold → Buy
2020-09-22	Downgrade	Guggenheim	Buy → Neutral
2020-06-01	Downgrade	Jefferies	Buy → Hold
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-03-24	Aggiornamento	Wedbush	Neutral → Outperform
2020-03-04	Iniziato	Barclays	Equal Weight
2019-11-20	Iniziato	Guggenheim	Buy
2019-11-11	Downgrade	Wedbush	Outperform → Neutral
2019-06-13	Iniziato	Mizuho	Buy
2019-05-14	Iniziato	Cantor Fitzgerald	Overweight
2019-03-11	Iniziato	Barclays	Overweight
2018-11-26	Iniziato	Piper Jaffray	Overweight
2018-10-15	Iniziato	Goldman	Neutral
2018-09-13	Iniziato	H.C. Wainwright	Buy
2018-06-01	Iniziato	SunTrust	Buy
2018-01-05	Iniziato	Citigroup	Buy
2017-09-08	Iniziato	Wedbush	Outperform
2017-03-27	Iniziato	H.C. Wainwright	Buy
2017-03-02	Iniziato	Instinet	Buy
2017-01-03	Downgrade	Oppenheimer	Outperform → Perform
2015-11-02	Iniziato	Oppenheimer	Outperform

Mostra tutto

Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie

03:13 AM

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World

03:13 AM

Dec 20, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024

Dec 18, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN

Dec 18, 2024

Dec 17, 2024

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St

Dec 17, 2024

Dec 16, 2024

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Dec 16, 2024

Dec 13, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 10, 2024

Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat

Dec 10, 2024

Dec 06, 2024

Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St

Dec 06, 2024

Nov 30, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat

Nov 30, 2024

Nov 28, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World

Nov 28, 2024

Nov 27, 2024

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times

Nov 27, 2024

Nov 25, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat

Nov 25, 2024

Nov 19, 2024

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India

Nov 15, 2024

Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com

Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024

Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024

Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024

Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024